In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and non-hospital sites of care. CRA’s expert found that in most uses, during the relevant time period there was ample evidence of competition, finding that the manufacturer at issue was effectively price constrained by existing competition.
Broadcom/VMware: Navigating foreclosure theories across different jurisdictions
This case presented numerous conceptual challenges, notably the differing outcomes of the competitive assessments across 12 jurisdictions. While Broadcom was...